Uncategorized

Canada’s Drug Agency (CDA-AMC) recommends that Keytruda be reimbursed by public drug plans for the treatment of primary advanced or […]

Conventional central line insertion technique using the landmark method to identify the target vein for catheter insertion does not account

Neuronal ceroid lipofuscinosis type 2 (CLN2) disease is an ultrarare, severe, and rapidly progressing lysosomal storage disorder, with a global

Post Content ​ 

Canada’s Drug Agency (CDA-AMC) recommends that Sarclisa be reimbursed by public drug plans for the treatment of patients with newly

Influenza is a major public health concern, causing significant illness, death, economic challenges, and pandemic potential. This underscores the need

Post Content ​ 

Offering additional pre-exposure prophylaxis (PrEP) choices has the potential to increase uptake and effective use of PrEP, and of HIV

Spinal muscular atrophy (SMA) is a rare genetic condition that affects muscle strength and movement in both children and adults.

Post Content ​